De_Monitor
$PHAR INVESTORS should watch $PHVS and $NTLA closely. Pharvaris is advancing a highly effective oral treatment for HAE attacks, while Intellia’s revolutionary one-time CRISPR therapy has shown sustained results for up to FOUR YEARS. Both face major regulatory milestones and could seriously disrupt the market Ruconest depends on. Two different technologies, one enormous threat to Pharming’s core business.
Here’s the problem: Ruconest still generates approximately 80% of Pharming’s quarterly revenue. It’s the company’s only major revenue pillar, with Joenja still too small to offset a substantial decline. Pharvaris could replace injections with convenient pills, while Intellia could dramatically reduce the need for lifelong HAE medication. Regulatory approval and commercial success aren’t guaranteed, but the threat is increasingly real. The question is no longer whether Ruconest faces serious competition, but how much of its market will survive. $PHVS $NTLA
3
